Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 06/22/22
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in MassachusettsGlobeNewsWire • 06/16/22
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant CongressGlobeNewsWire • 06/09/22
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for VirologyGlobeNewsWire • 06/08/22
Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for VirologyGlobeNewsWire • 06/08/22
Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International ConventionGlobeNewsWire • 06/06/22
Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant CongressGlobeNewsWire • 05/31/22
Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, TreatmentsInvestorPlace • 05/20/22
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2GlobeNewsWire • 05/18/22